E Fund Management Co. Ltd. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

E Fund Management Co. Ltd. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,384 shares of the biopharmaceutical company’s stock after selling 5,002 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Halozyme Therapeutics were worth $663,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the fourth quarter worth about $29,000. Bessemer Group Inc. lifted its position in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares during the period. Park Place Capital Corp lifted its position in Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 182 shares during the period. UMB Bank n.a. lifted its position in Halozyme Therapeutics by 267.4% during the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 960 shares during the period. Finally, CWM LLC lifted its position in Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 438 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

HALO stock opened at $65.13 on Thursday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.50. The firm has a market cap of $8.03 billion, a P/E ratio of 14.90, a price-to-earnings-growth ratio of 0.35 and a beta of 1.17. The stock has a 50-day simple moving average of $56.56 and a 200-day simple moving average of $58.10.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter last year, the firm earned $0.91 earnings per share. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 80,000 shares of company stock valued at $4,532,600 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on HALO shares. Morgan Stanley upgraded Halozyme Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $62.00 to $75.00 in a report on Wednesday, August 6th. Leerink Partnrs downgraded Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price objective on the stock. HC Wainwright raised their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Finally, Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Hold” and an average price target of $66.56.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.